azithromycin - versus potential COVID-19 treatments - for COVID 19 outpatients pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 1.65 [0.03, 83.12]< 10%1 study (1/-)40.3 %NAnot evaluable crucial-
hospitalization or death 0.91 [0.43, 1.92]< 10%1 study (1/-)59.8 %NAnot evaluable crucial-
A EFFACER PCR-negative (end of follow-up) 0.91 [0.57, 1.46]> 10%1 study (1/-)34.7 %NAnot evaluable important-
clinical improvement 1.08 [0.95, 1.23]> 10%1 study (1/-)87.9 %NAnot evaluable important-
clinical improvement (14-day) 1.01 [0.75, 1.37]> 10%1 study (1/-)52.6 %NAnot evaluable important-
clinical improvement (time to event analysis only) 1.08 [0.95, 1.23]> 10%1 study (1/-)87.9 %NAnot evaluable important-
hospitalization 0.94 [0.59, 1.51]< 10%2 studies (2/-)59.5 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.50 [0.10, 2.60]< 10%1 study (1/-)79.4 %NAnot evaluable important-
ICU admission 0.76 [0.18, 3.18]< 10%1 study (1/-)64.8 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.